Nintedanib Ethanesulfonate Salt (Synonyms: Intedanib; BIBF 1120; )| CAS 656247-18-6

规格	库存	目录价	会员专享价	数量
10 mg	In-stock	￥288.00	登录后可见	- +
25 mg	In-stock	￥500.00	登录后可见	- +
50 mg	In-stock	￥900.00	登录后可见	- +
100 mg	In-stock	￥1300.00	登录后可见	- +

规格

库存

目录价

会员专享价

数量

10 mg

In-stock

￥288.00

登录后可见

- +

25 mg

In-stock

￥500.00

登录后可见

- +

50 mg

In-stock

￥900.00

登录后可见

- +

100 mg

In-stock

￥1300.00

登录后可见

- +

基本信息

英文名称	Nintedanib Ethanesulfonate Salt (Synonyms: Intedanib; BIBF 1120)
中文名称	(Z)-3-(((4-(N-甲基-2-(4-甲基哌嗪-1-基)乙酰氨基)苯基)氨基)(苯基)亚甲基)-2-氧代吲哚啉-6-羧酸甲酯乙磺酸盐; 尼达尼布乙磺酸盐
CAS号	656247-18-6
分子式	C31H33N5O4.C2H6O3S
分子量	649.76 \| 539.64(free)
MDL	MFCD26142360
外观	Yellow powder
储存条件	4°C, sealed storage, away from moisture

产品详情

BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively).1 It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs; EC50s = 7-290 nM). In vivo, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).

(Z)-3-(((4-(N-甲基-2-(4-甲基哌嗪-1-基)乙酰氨基)苯基)氨基)(苯基)亚甲基)-2-氧代吲哚啉-6-羧酸甲酯乙磺酸盐; 尼达尼布乙磺酸盐

Nintedanib Ethanesulfonate Salt (Synonyms: Intedanib; BIBF 1120)

化学品安全说明书(MSDS)

质检证书(COA)